Thursday, May 7, 2015, Celgene will present at the Deutsche Bank 40th Annual Health Care Conference in Boston at 9:20 am ET
Tuesday, May 12, 2015, Celgene will present at the Bank of America Merrill Lynch 2015 Health Care Conference in Las Vegas at 1:40 pm ET
Sunday, May 17, 2015, Celgene will present at the Digestive Disease Week Annual Meeting in Washington, D.C. at 6:30 pm ET
Thursday, May 28, 2015 Celgene will present at the Sanford C. Bernstein 31st Annual Strategic Decisions Conference in New York at 3:00 pm ET
Sunday, May 31, 2015, Celgene will present at the American Society of Clinical Oncology Annual Meeting in Chicago at 7:30 pm ET
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit www.celgene.com. Follow Celgene on Social Media: @Celgene, Pinterest,LinkedIn and YouTube.
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.
Patrick E. Flanigan III, 908-673-9969
VP, Investor Relations
Brian Gill, 908-673-9530
VP, Corporate Communications